
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual ... Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2401 | -6.03266331658 | 3.98 | 4.462 | 3.5419 | 33233 | 3.92477821 | CS |
4 | 0.9999 | 36.4927007299 | 2.74 | 5.2683 | 2.65 | 207331 | 3.75790042 | CS |
12 | 1.3399 | 55.8291666667 | 2.4 | 5.2683 | 2.3955 | 70803 | 3.70167135 | CS |
26 | -0.4001 | -9.66425120773 | 4.14 | 5.2683 | 2.2 | 36579 | 3.66465859 | CS |
52 | -0.4501 | -10.7422434368 | 4.19 | 5.2683 | 2.2 | 27723 | 3.77581568 | CS |
156 | -6.0601 | -61.837755102 | 9.8 | 10 | 2.2 | 28384 | 4.58723346 | CS |
260 | -6.9601 | -65.0476635514 | 10.7 | 58.5 | 2.2 | 799650 | 28.61681874 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.